Patents by Inventor Rajeeva Singh
Rajeeva Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9376500Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: December 3, 2013Date of Patent: June 28, 2016Assignee: ImmunoGen, Inc.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
-
Patent number: 9353127Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.Type: GrantFiled: February 15, 2012Date of Patent: May 31, 2016Assignee: ImmunoGen, Inc.Inventors: Nathan Fishkin, Michael Miller, Wei Li, Rajeeva Singh
-
Publication number: 20160114052Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.Type: ApplicationFiled: August 25, 2015Publication date: April 28, 2016Applicant: IMMUNOGEN, INC.Inventors: Rajeeva Singh, Yelena Kovtun, Sharon D. Wilhelm, Ravi V.J. Chari
-
Publication number: 20160017053Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: ApplicationFiled: May 8, 2015Publication date: January 21, 2016Applicant: ImmunoGen, Inc.Inventors: Julianto SETIADY, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden
-
Patent number: 9238690Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: GrantFiled: October 28, 2011Date of Patent: January 19, 2016Assignee: ImmunoGen, Inc.Inventors: Julianto Setiady, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden
-
Publication number: 20150352223Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: May 15, 2015Publication date: December 10, 2015Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
-
Patent number: 9150649Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.Type: GrantFiled: October 6, 2009Date of Patent: October 6, 2015Assignee: ImmunoGen, Inc.Inventors: Rajeeva Singh, Yelena Kovtun, Sharon D. Wilhelm, Ravi V. J. Chari
-
Patent number: 9061995Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: GrantFiled: November 14, 2013Date of Patent: June 23, 2015Assignee: ImmunoGen, Inc.Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
-
Publication number: 20140179906Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.Type: ApplicationFiled: December 3, 2013Publication date: June 26, 2014Applicant: ImmunoGen, Inc.Inventors: Brenda A. KELLOGG, Rajeeva SINGH, Ravi V. J. CHARI
-
Publication number: 20140178416Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: November 14, 2013Publication date: June 26, 2014Applicant: IMMUNOGEN, INC.Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
-
Publication number: 20140023662Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: ApplicationFiled: October 28, 2011Publication date: January 23, 2014Applicant: ImmunoGen, Inc.Inventors: Julianto Setiady, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden
-
Patent number: 8624003Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: June 3, 2010Date of Patent: January 7, 2014Assignee: ImmunoGen, Inc.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
-
Patent number: 8613930Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: GrantFiled: July 5, 2012Date of Patent: December 24, 2013Assignee: ImmunoGen, Inc.Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne Charles Widdison
-
Publication number: 20130295050Abstract: DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: ApplicationFiled: September 14, 2012Publication date: November 7, 2013Applicant: IMMUNOGEN, INC.Inventors: Rajeeva SINGH, Daniel J. TAVARES, Nancy E. DAGDIGIAN
-
Publication number: 20130011419Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: July 5, 2012Publication date: January 10, 2013Applicant: ImmunoGen, INC.Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne Charles Widdison
-
Publication number: 20120238731Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.Type: ApplicationFiled: February 15, 2012Publication date: September 20, 2012Applicant: ImmunoGen, Inc.Inventors: Nathan Fishkin, Michael Miller, Wei Li, Rajeeva Singh
-
Patent number: 8268617Abstract: DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: August 26, 2009Date of Patent: September 18, 2012Assignee: ImmunoGen, Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Publication number: 20120226026Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.Type: ApplicationFiled: May 17, 2012Publication date: September 6, 2012Applicant: IMMUNOGEN, INC.Inventors: Rajeeva SINGH, Sharon D. WILHELM, Ravi V.J. CHARI
-
Patent number: 8236319Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: GrantFiled: April 30, 2009Date of Patent: August 7, 2012Assignee: ImmunoGen, Inc.Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne Charles Widdison
-
Patent number: 8034904Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: December 8, 2003Date of Patent: October 11, 2011Assignee: Immunogen Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian